nodes	percent_of_prediction	percent_of_DWPC	metapath
Travoprost—Retinal pigmentation—Cisplatin—esophageal cancer	0.245	0.275	CcSEcCtD
Travoprost—PTGFR—bronchus—esophageal cancer	0.0261	0.252	CbGeAlD
Travoprost—PTGFR—smooth muscle tissue—esophageal cancer	0.0255	0.247	CbGeAlD
Travoprost—Punctate keratitis—Capecitabine—esophageal cancer	0.0248	0.0278	CcSEcCtD
Travoprost—PTGFR—trachea—esophageal cancer	0.0234	0.227	CbGeAlD
Travoprost—Ocular discomfort—Methotrexate—esophageal cancer	0.0205	0.023	CcSEcCtD
Travoprost—Scab—Capecitabine—esophageal cancer	0.0197	0.0221	CcSEcCtD
Travoprost—PTGFR—lung—esophageal cancer	0.0168	0.163	CbGeAlD
Travoprost—Drug hypersensitivity—Capecitabine—esophageal cancer	0.0155	0.0174	CcSEcCtD
Travoprost—PTGFR—lymph node—esophageal cancer	0.0115	0.111	CbGeAlD
Travoprost—Visual acuity reduced—Capecitabine—esophageal cancer	0.0105	0.0118	CcSEcCtD
Travoprost—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.0105	0.0118	CcSEcCtD
Travoprost—Infection—Carboplatin—esophageal cancer	0.0103	0.0115	CcSEcCtD
Travoprost—Tenderness—Cisplatin—esophageal cancer	0.00974	0.0109	CcSEcCtD
Travoprost—Keratitis—Capecitabine—esophageal cancer	0.00965	0.0108	CcSEcCtD
Travoprost—Pain—Carboplatin—esophageal cancer	0.00883	0.00991	CcSEcCtD
Travoprost—Metrorrhagia—Capecitabine—esophageal cancer	0.00877	0.00984	CcSEcCtD
Travoprost—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.00784	0.00879	CcSEcCtD
Travoprost—Dysphonia—Capecitabine—esophageal cancer	0.00761	0.00854	CcSEcCtD
Travoprost—Eye irritation—Capecitabine—esophageal cancer	0.00733	0.00823	CcSEcCtD
Travoprost—Skin discolouration—Capecitabine—esophageal cancer	0.00693	0.00778	CcSEcCtD
Travoprost—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00689	0.00773	CcSEcCtD
Travoprost—Lacrimation increased—Capecitabine—esophageal cancer	0.00679	0.00762	CcSEcCtD
Travoprost—Herpes simplex—Capecitabine—esophageal cancer	0.00679	0.00762	CcSEcCtD
Travoprost—Nasal congestion—Cisplatin—esophageal cancer	0.00677	0.00759	CcSEcCtD
Travoprost—Cataract—Capecitabine—esophageal cancer	0.00658	0.00738	CcSEcCtD
Travoprost—Inflammation—Capecitabine—esophageal cancer	0.00645	0.00724	CcSEcCtD
Travoprost—Blood pressure increased—Capecitabine—esophageal cancer	0.00626	0.00703	CcSEcCtD
Travoprost—Urinary incontinence—Capecitabine—esophageal cancer	0.00605	0.00678	CcSEcCtD
Travoprost—Dry eye—Capecitabine—esophageal cancer	0.00578	0.00649	CcSEcCtD
Travoprost—Abnormal vision—Capecitabine—esophageal cancer	0.00546	0.00613	CcSEcCtD
Travoprost—Tafluprost—PTGS2—esophageal cancer	0.00543	1	CrCbGaD
Travoprost—Skin discolouration—Methotrexate—esophageal cancer	0.00516	0.00579	CcSEcCtD
Travoprost—Bone disorder—Methotrexate—esophageal cancer	0.00516	0.00579	CcSEcCtD
Travoprost—Herpes simplex—Methotrexate—esophageal cancer	0.00506	0.00568	CcSEcCtD
Travoprost—Eye pain—Capecitabine—esophageal cancer	0.00503	0.00565	CcSEcCtD
Travoprost—Inflammation—Methotrexate—esophageal cancer	0.00481	0.00539	CcSEcCtD
Travoprost—Arthritis—Capecitabine—esophageal cancer	0.00468	0.00525	CcSEcCtD
Travoprost—Conjunctivitis—Cisplatin—esophageal cancer	0.00462	0.00518	CcSEcCtD
Travoprost—Bradycardia—Cisplatin—esophageal cancer	0.00434	0.00487	CcSEcCtD
Travoprost—Urinary tract disorder—Cisplatin—esophageal cancer	0.00421	0.00473	CcSEcCtD
Travoprost—Connective tissue disorder—Cisplatin—esophageal cancer	0.00419	0.0047	CcSEcCtD
Travoprost—Urethral disorder—Cisplatin—esophageal cancer	0.00418	0.00469	CcSEcCtD
Travoprost—Visual impairment—Cisplatin—esophageal cancer	0.00411	0.00461	CcSEcCtD
Travoprost—Eye disorder—Cisplatin—esophageal cancer	0.00399	0.00447	CcSEcCtD
Travoprost—Tinnitus—Cisplatin—esophageal cancer	0.00398	0.00446	CcSEcCtD
Travoprost—Cardiac disorder—Cisplatin—esophageal cancer	0.00396	0.00444	CcSEcCtD
Travoprost—Influenza—Capecitabine—esophageal cancer	0.00393	0.00441	CcSEcCtD
Travoprost—Asthma—Capecitabine—esophageal cancer	0.00393	0.00441	CcSEcCtD
Travoprost—Immune system disorder—Cisplatin—esophageal cancer	0.00385	0.00432	CcSEcCtD
Travoprost—Mediastinal disorder—Cisplatin—esophageal cancer	0.00384	0.00431	CcSEcCtD
Travoprost—Angina pectoris—Capecitabine—esophageal cancer	0.00383	0.00429	CcSEcCtD
Travoprost—Bronchitis—Capecitabine—esophageal cancer	0.00378	0.00424	CcSEcCtD
Travoprost—Erythema—Cisplatin—esophageal cancer	0.00371	0.00417	CcSEcCtD
Travoprost—Dysuria—Capecitabine—esophageal cancer	0.00367	0.00412	CcSEcCtD
Travoprost—Infestation NOS—Capecitabine—esophageal cancer	0.0035	0.00393	CcSEcCtD
Travoprost—Infestation—Capecitabine—esophageal cancer	0.0035	0.00393	CcSEcCtD
Travoprost—Vision blurred—Cisplatin—esophageal cancer	0.0035	0.00393	CcSEcCtD
Travoprost—Depression—Capecitabine—esophageal cancer	0.00349	0.00392	CcSEcCtD
Travoprost—Ill-defined disorder—Cisplatin—esophageal cancer	0.00345	0.00387	CcSEcCtD
Travoprost—Conjunctivitis—Capecitabine—esophageal cancer	0.0034	0.00382	CcSEcCtD
Travoprost—Urinary tract infection—Capecitabine—esophageal cancer	0.0034	0.00382	CcSEcCtD
Travoprost—Malaise—Cisplatin—esophageal cancer	0.00335	0.00376	CcSEcCtD
Travoprost—Bradycardia—Capecitabine—esophageal cancer	0.0032	0.00359	CcSEcCtD
Travoprost—Myalgia—Cisplatin—esophageal cancer	0.00316	0.00355	CcSEcCtD
Travoprost—Rhinitis—Capecitabine—esophageal cancer	0.00315	0.00354	CcSEcCtD
Travoprost—Anxiety—Cisplatin—esophageal cancer	0.00315	0.00353	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00314	0.00352	CcSEcCtD
Travoprost—Discomfort—Cisplatin—esophageal cancer	0.00312	0.0035	CcSEcCtD
Travoprost—Pharyngitis—Capecitabine—esophageal cancer	0.00312	0.0035	CcSEcCtD
Travoprost—Urinary tract disorder—Capecitabine—esophageal cancer	0.00311	0.00348	CcSEcCtD
Travoprost—Connective tissue disorder—Capecitabine—esophageal cancer	0.00309	0.00347	CcSEcCtD
Travoprost—Urethral disorder—Capecitabine—esophageal cancer	0.00308	0.00346	CcSEcCtD
Travoprost—Oedema—Cisplatin—esophageal cancer	0.00303	0.0034	CcSEcCtD
Travoprost—Visual impairment—Capecitabine—esophageal cancer	0.00303	0.0034	CcSEcCtD
Travoprost—Infection—Cisplatin—esophageal cancer	0.00301	0.00338	CcSEcCtD
Travoprost—Nervous system disorder—Cisplatin—esophageal cancer	0.00297	0.00333	CcSEcCtD
Travoprost—Tachycardia—Cisplatin—esophageal cancer	0.00296	0.00332	CcSEcCtD
Travoprost—Skin disorder—Cisplatin—esophageal cancer	0.00294	0.0033	CcSEcCtD
Travoprost—Eye disorder—Capecitabine—esophageal cancer	0.00294	0.0033	CcSEcCtD
Travoprost—Tinnitus—Capecitabine—esophageal cancer	0.00293	0.00329	CcSEcCtD
Travoprost—Asthma—Methotrexate—esophageal cancer	0.00292	0.00328	CcSEcCtD
Travoprost—Cardiac disorder—Capecitabine—esophageal cancer	0.00292	0.00327	CcSEcCtD
Travoprost—Angiopathy—Capecitabine—esophageal cancer	0.00285	0.0032	CcSEcCtD
Travoprost—Immune system disorder—Capecitabine—esophageal cancer	0.00284	0.00319	CcSEcCtD
Travoprost—Mediastinal disorder—Capecitabine—esophageal cancer	0.00283	0.00318	CcSEcCtD
Travoprost—Hypotension—Cisplatin—esophageal cancer	0.00283	0.00318	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00276	0.0031	CcSEcCtD
Travoprost—Mental disorder—Capecitabine—esophageal cancer	0.00275	0.00309	CcSEcCtD
Travoprost—Erythema—Capecitabine—esophageal cancer	0.00274	0.00307	CcSEcCtD
Travoprost—Dysuria—Methotrexate—esophageal cancer	0.00273	0.00307	CcSEcCtD
Travoprost—Dyspnoea—Cisplatin—esophageal cancer	0.0027	0.00303	CcSEcCtD
Travoprost—Dysgeusia—Capecitabine—esophageal cancer	0.00268	0.00301	CcSEcCtD
Travoprost—Back pain—Capecitabine—esophageal cancer	0.00265	0.00297	CcSEcCtD
Travoprost—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00262	0.00294	CcSEcCtD
Travoprost—Infestation—Methotrexate—esophageal cancer	0.00261	0.00293	CcSEcCtD
Travoprost—Infestation NOS—Methotrexate—esophageal cancer	0.00261	0.00293	CcSEcCtD
Travoprost—Depression—Methotrexate—esophageal cancer	0.0026	0.00292	CcSEcCtD
Travoprost—Pain—Cisplatin—esophageal cancer	0.00259	0.00291	CcSEcCtD
Travoprost—Vision blurred—Capecitabine—esophageal cancer	0.00258	0.00289	CcSEcCtD
Travoprost—Ill-defined disorder—Capecitabine—esophageal cancer	0.00254	0.00285	CcSEcCtD
Travoprost—Conjunctivitis—Methotrexate—esophageal cancer	0.00253	0.00284	CcSEcCtD
Travoprost—Feeling abnormal—Cisplatin—esophageal cancer	0.0025	0.0028	CcSEcCtD
Travoprost—Malaise—Capecitabine—esophageal cancer	0.00247	0.00277	CcSEcCtD
Travoprost—Vertigo—Capecitabine—esophageal cancer	0.00246	0.00276	CcSEcCtD
Travoprost—Palpitations—Capecitabine—esophageal cancer	0.00242	0.00271	CcSEcCtD
Travoprost—Cough—Capecitabine—esophageal cancer	0.00239	0.00268	CcSEcCtD
Travoprost—Hypertension—Capecitabine—esophageal cancer	0.00236	0.00265	CcSEcCtD
Travoprost—Chest pain—Capecitabine—esophageal cancer	0.00233	0.00261	CcSEcCtD
Travoprost—Myalgia—Capecitabine—esophageal cancer	0.00233	0.00261	CcSEcCtD
Travoprost—Arthralgia—Capecitabine—esophageal cancer	0.00233	0.00261	CcSEcCtD
Travoprost—Pharyngitis—Methotrexate—esophageal cancer	0.00232	0.00261	CcSEcCtD
Travoprost—Anxiety—Capecitabine—esophageal cancer	0.00232	0.00261	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00231	0.0026	CcSEcCtD
Travoprost—Urinary tract disorder—Methotrexate—esophageal cancer	0.00231	0.00259	CcSEcCtD
Travoprost—Discomfort—Capecitabine—esophageal cancer	0.0023	0.00258	CcSEcCtD
Travoprost—Urethral disorder—Methotrexate—esophageal cancer	0.00229	0.00257	CcSEcCtD
Travoprost—Dry mouth—Capecitabine—esophageal cancer	0.00228	0.00256	CcSEcCtD
Travoprost—Visual impairment—Methotrexate—esophageal cancer	0.00226	0.00253	CcSEcCtD
Travoprost—Oedema—Capecitabine—esophageal cancer	0.00223	0.00251	CcSEcCtD
Travoprost—Hypersensitivity—Cisplatin—esophageal cancer	0.00223	0.00251	CcSEcCtD
Travoprost—Infection—Capecitabine—esophageal cancer	0.00222	0.00249	CcSEcCtD
Travoprost—Nervous system disorder—Capecitabine—esophageal cancer	0.00219	0.00246	CcSEcCtD
Travoprost—Eye disorder—Methotrexate—esophageal cancer	0.00219	0.00245	CcSEcCtD
Travoprost—Tinnitus—Methotrexate—esophageal cancer	0.00218	0.00245	CcSEcCtD
Travoprost—Tachycardia—Capecitabine—esophageal cancer	0.00218	0.00245	CcSEcCtD
Travoprost—Asthenia—Cisplatin—esophageal cancer	0.00217	0.00244	CcSEcCtD
Travoprost—Cardiac disorder—Methotrexate—esophageal cancer	0.00217	0.00244	CcSEcCtD
Travoprost—Skin disorder—Capecitabine—esophageal cancer	0.00217	0.00243	CcSEcCtD
Travoprost—Angiopathy—Methotrexate—esophageal cancer	0.00212	0.00238	CcSEcCtD
Travoprost—Immune system disorder—Methotrexate—esophageal cancer	0.00211	0.00237	CcSEcCtD
Travoprost—Mediastinal disorder—Methotrexate—esophageal cancer	0.00211	0.00237	CcSEcCtD
Travoprost—Hypotension—Capecitabine—esophageal cancer	0.00209	0.00234	CcSEcCtD
Travoprost—Diarrhoea—Cisplatin—esophageal cancer	0.00207	0.00233	CcSEcCtD
Travoprost—Mental disorder—Methotrexate—esophageal cancer	0.00205	0.0023	CcSEcCtD
Travoprost—Erythema—Methotrexate—esophageal cancer	0.00204	0.00229	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00204	0.00228	CcSEcCtD
Travoprost—Dysgeusia—Methotrexate—esophageal cancer	0.002	0.00224	CcSEcCtD
Travoprost—Dyspnoea—Capecitabine—esophageal cancer	0.00199	0.00223	CcSEcCtD
Travoprost—Back pain—Methotrexate—esophageal cancer	0.00197	0.00221	CcSEcCtD
Travoprost—Dyspepsia—Capecitabine—esophageal cancer	0.00197	0.00221	CcSEcCtD
Travoprost—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00193	0.00216	CcSEcCtD
Travoprost—Fatigue—Capecitabine—esophageal cancer	0.00193	0.00216	CcSEcCtD
Travoprost—Vision blurred—Methotrexate—esophageal cancer	0.00192	0.00215	CcSEcCtD
Travoprost—Rash—Cisplatin—esophageal cancer	0.00191	0.00214	CcSEcCtD
Travoprost—Pain—Capecitabine—esophageal cancer	0.00191	0.00214	CcSEcCtD
Travoprost—Constipation—Capecitabine—esophageal cancer	0.00191	0.00214	CcSEcCtD
Travoprost—Dermatitis—Cisplatin—esophageal cancer	0.00191	0.00214	CcSEcCtD
Travoprost—Ill-defined disorder—Methotrexate—esophageal cancer	0.00189	0.00212	CcSEcCtD
Travoprost—Feeling abnormal—Capecitabine—esophageal cancer	0.00184	0.00207	CcSEcCtD
Travoprost—Malaise—Methotrexate—esophageal cancer	0.00184	0.00206	CcSEcCtD
Travoprost—Vertigo—Methotrexate—esophageal cancer	0.00183	0.00205	CcSEcCtD
Travoprost—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00183	0.00205	CcSEcCtD
Travoprost—Nausea—Cisplatin—esophageal cancer	0.0018	0.00202	CcSEcCtD
Travoprost—Cough—Methotrexate—esophageal cancer	0.00178	0.002	CcSEcCtD
Travoprost—Abdominal pain—Capecitabine—esophageal cancer	0.00177	0.00198	CcSEcCtD
Travoprost—Arthralgia—Methotrexate—esophageal cancer	0.00173	0.00195	CcSEcCtD
Travoprost—Myalgia—Methotrexate—esophageal cancer	0.00173	0.00195	CcSEcCtD
Travoprost—Chest pain—Methotrexate—esophageal cancer	0.00173	0.00195	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00172	0.00193	CcSEcCtD
Travoprost—Discomfort—Methotrexate—esophageal cancer	0.00171	0.00192	CcSEcCtD
Travoprost—Infection—Methotrexate—esophageal cancer	0.00165	0.00185	CcSEcCtD
Travoprost—Hypersensitivity—Capecitabine—esophageal cancer	0.00165	0.00185	CcSEcCtD
Travoprost—Nervous system disorder—Methotrexate—esophageal cancer	0.00163	0.00183	CcSEcCtD
Travoprost—Skin disorder—Methotrexate—esophageal cancer	0.00162	0.00181	CcSEcCtD
Travoprost—Asthenia—Capecitabine—esophageal cancer	0.0016	0.0018	CcSEcCtD
Travoprost—Pruritus—Capecitabine—esophageal cancer	0.00158	0.00177	CcSEcCtD
Travoprost—Hypotension—Methotrexate—esophageal cancer	0.00155	0.00174	CcSEcCtD
Travoprost—Diarrhoea—Capecitabine—esophageal cancer	0.00153	0.00172	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00152	0.0017	CcSEcCtD
Travoprost—Dyspnoea—Methotrexate—esophageal cancer	0.00148	0.00166	CcSEcCtD
Travoprost—Dizziness—Capecitabine—esophageal cancer	0.00148	0.00166	CcSEcCtD
Travoprost—Dyspepsia—Methotrexate—esophageal cancer	0.00146	0.00164	CcSEcCtD
Travoprost—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00144	0.00161	CcSEcCtD
Travoprost—Fatigue—Methotrexate—esophageal cancer	0.00143	0.00161	CcSEcCtD
Travoprost—Pain—Methotrexate—esophageal cancer	0.00142	0.0016	CcSEcCtD
Travoprost—Rash—Capecitabine—esophageal cancer	0.00141	0.00158	CcSEcCtD
Travoprost—Dermatitis—Capecitabine—esophageal cancer	0.00141	0.00158	CcSEcCtD
Travoprost—Headache—Capecitabine—esophageal cancer	0.0014	0.00157	CcSEcCtD
Travoprost—Feeling abnormal—Methotrexate—esophageal cancer	0.00137	0.00154	CcSEcCtD
Travoprost—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00136	0.00153	CcSEcCtD
Travoprost—Nausea—Capecitabine—esophageal cancer	0.00133	0.00149	CcSEcCtD
Travoprost—Abdominal pain—Methotrexate—esophageal cancer	0.00131	0.00148	CcSEcCtD
Travoprost—Hypersensitivity—Methotrexate—esophageal cancer	0.00123	0.00137	CcSEcCtD
Travoprost—Asthenia—Methotrexate—esophageal cancer	0.00119	0.00134	CcSEcCtD
Travoprost—Pruritus—Methotrexate—esophageal cancer	0.00118	0.00132	CcSEcCtD
Travoprost—Diarrhoea—Methotrexate—esophageal cancer	0.00114	0.00128	CcSEcCtD
Travoprost—Dizziness—Methotrexate—esophageal cancer	0.0011	0.00123	CcSEcCtD
Travoprost—Rash—Methotrexate—esophageal cancer	0.00105	0.00118	CcSEcCtD
Travoprost—Dermatitis—Methotrexate—esophageal cancer	0.00105	0.00118	CcSEcCtD
Travoprost—Headache—Methotrexate—esophageal cancer	0.00104	0.00117	CcSEcCtD
Travoprost—Nausea—Methotrexate—esophageal cancer	0.000988	0.00111	CcSEcCtD
